{"id":"metformin-and-insulin-sc","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Metformin inhibits the enzyme complex mitochondrial glycerophosphate dehydrogenase, which is involved in gluconeogenesis. Insulin sc, on the other hand, mimics the action of the body's natural insulin, facilitating glucose uptake in cells and suppressing glucose production in the liver.","oneSentence":"Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while insulin sc works by replacing or supplementing the body's natural insulin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:54.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06297603","phase":"PHASE3","title":"Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-03-15","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT05260021","phase":"PHASE3","title":"A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-04-13","conditions":"Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":99},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT05952882","phase":"PHASE3","title":"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-11-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":188},{"nctId":"NCT04591626","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT04093752","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-09","conditions":"Type 2 Diabetes","enrollment":917},{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT04039503","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-08-30","conditions":"Type 2 Diabetes","enrollment":475},{"nctId":"NCT03951805","phase":"PHASE2","title":"A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":205},{"nctId":"NCT02561130","phase":"PHASE4","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT03130426","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-06-27","conditions":"Type 2 Diabetes Mellitus","enrollment":161},{"nctId":"NCT01181674","phase":"PHASE4","title":"Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2011-01","conditions":"Type 2 Diabetes Mellitus","enrollment":83},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT01786707","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Rodolfo Alejandro","startDate":"2009-07","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT02058147","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":1170},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01476475","phase":"PHASE2","title":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":323},{"nctId":"NCT01051011","phase":"PHASE3","title":"A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Diabetes Mellitus Type 2","enrollment":370},{"nctId":"NCT01075282","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":810},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT00935805","phase":"","title":"Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-07","conditions":"Diabetes Mellitus, Arterial Hypertension","enrollment":124},{"nctId":"NCT01035528","phase":"PHASE4","title":"Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)","status":"UNKNOWN","sponsor":"Munich Municipal Hospital","startDate":"2005-04","conditions":"Coronary Artery Disease, Type 2 Diabetes","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Siofor, Lantus"],"phase":"phase_3","status":"active","brandName":"Metformin and Insulin sc","genericName":"Metformin and Insulin sc","companyName":"Institut für Pharmakologie und Präventive Medizin","companyId":"institut-f-r-pharmakologie-und-pr-ventive-medizin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while insulin sc works by replacing or supplementing the body's natural insulin. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}